Broadview Ventures

Portfolio Name: Nyra Medical

Nyra Medical, a spinout of Emory University, is developing a novel device to treat mitral regurgitation (MR), a severe heart condition in which the mitral valve between the left atrium and left ventricle does not seal properly, resulting in leakage of blood backward through the mitral valve each time the left ventricle contracts MR can lead to enlargement of the atrium and ventricle, abnormal heart rhythms, pulmonary hypertension, and heart failure Nyra’s cardiac leaflet enhancer (CARLEN) is a first-in-class device delivered percutaneously to correct MR while preserving the physiological valve geometry

Portfolio Name: Puzzle Medical Devices

Puzzle Medical Devices Inc is developing ModulHeart, a percutaneous heart pump for patients with advanced HF The device’s modular design allows for hemodynamic support through multiple parallel endovascular pumps anchored in the descending aorta This novel design results in low pump speeds, secure aortic anchoring, and positioning distal to the cerebral arteries As a result, the device is expected to preserve blood integrity, reduce the risk of embolic events, enable ambulatory and outpatient use These attributes will allow for safe long-term implantation, with minimal risk of bleeding, stroke, and pump thrombosis

RapidPulse is developing a novel cyclic aspiration system enabling rapid and consistent mechanical thrombectomy of blood clots for the treatment of acute ischemic stroke

Portfolio Name: XII Medical

XII Medical is developing an innovative, minimally invasive technology to address obstructive sleep apnea (OSA), a condition affecting approximately 45 million people in the US OSA is characterized by recurrent, functional collapse of the upper airway during sleep, causing substantially reduced or complete cessation of airflow and leading to nocturnal hypoxemia Untreated OSA is associated with long term negative health outcomes, including an increased risk of cardiovascular disease, poor neurocognitive performance, reduced quality of life, and increased all-cause mortality Treating OSA has specifically been shown to improve disease markers across a range of cardiovascular conditions, yet many patients are unable to tolerate current therapeutic options, with adherence rates of roughly 50%

BioKier is developing a proprietary oral treatment for diabetes based on understanding the mechanism of the anti-diabetic effects of metabolic surgery and malabsorption as previously described Independent of its weight loss effect, metabolic surgery substantially improves or even resolves diabetes within days in 80 to 90 percent of obese Type 2 diabetes patients This surgery is equally effective in non-obese diabetes patients BioKier has devised a proprietary method to mimic the effects of intestinal shortening surgery and potentially improve or resolve diabetes without the physical trauma and cost of bariatric surgery Diabetes has long been recognized as a major contributor to the development of cardiovascular disease Heart disease and stroke are the major causes of death and disability among people with Type 2 diabetes

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U S healthcare industry – heart disease Capricor Therapeutics’ lead product candidates will target the prevention and treatment of heart failure and heart attacks Capricor’s allogeneic cardiosphere-derived cell (CDC) product, CAP-1002, aims to attenuate and potentially improve damage to the heart caused by a heart attack

Capricor’s translational approach to product development is based on the comprehensive research foundation provided through our academic partnerships with leading scientists at top-tier research institutions

Capricor and Nile Therapeutics completed a merger in 2013 to form Capricor Therapeutics, Inc (NASDAQ: CAPR)

Portfolio Name: Epirium Bio

Epirium is a clinical stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue regeneration, potentially resulting in novel and clinically significant therapeutic approaches to currently intractable neuromuscular and neurodegenerative diseases, including primary and secondary cardiomyopathies The Company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration Epirium intends to advance its first clinical candidate (EB 002) this year, initially in Becker muscular dystrophy, followed by drug development targeting other progressive neuromuscular and neurodegenerative disorders associated with mitochondrial depletion

Cardialen, Inc was formed in 2008 to develop and commercialize pain-free cardioversion therapy, with a primary focus on atrial fibrillation (AF) The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition AF is the most common cardiac arrhythmia worldwide and has been recently estimated to affect over 3 0 million people in the United States AF, unlike ventricular fibrillation (VF), is not immediately life threatening However, AF greatly increases the risk of stroke and premature death, impairs quality of life and generates high healthcare costs Current therapies (drugs, external cardioversion, catheter ablation and surgery of various types) do not fully meet AF patient needs

Portfolio Name: CardiAQ Valve Technologies

CardiAQ Valve Technologies (CVT) is developing the world’s first self-conforming and self-anchoring technology for transcatheter mitral valve implantation The initial indication for this percutaneous valve will be treating functional mitral regurgitation to prevent heart failure CVT is located in Irvine, California and is led by CEO Rob Michiels, formerly of CoreValve Three years after our initial investment CVT had attracted over $40M in follow on funding from angels and venture capital firms

CVT was acquired by Edwards Lifesciences in 2015

CellAegis Devices (Toronto, Canada) has patented and developed the non-invasive autoRIC Device, which delivers Remote Ischemic Conditioning (RIC) therapy to patients with acute and chronic cardiovascular conditions RIC therapy is based on the principle of adaptive physiology, where short, deliberate occlusion of blood flow to the arm activates the cellular survival network against ischemia This medical procedure protects the heart as well as other organs from ischemia and reperfusion injury

The autoRIC Device has CE Mark and Health Canada approval for adjunct treatment during heart attacks, cardiothoracic or surgical procedures, and is being developed for chronic conditions such as heart failure and stroke The autoRIC Device was developed from the clinical work of Dr Andrew Redington and colleagues, who are part of the Fondation Leducq TransAtlantic network

DecImmune is developing a monoclonal antibody therapeutic to mitigate injury post-myocardial infarction DecImmune’s technology works by preventing the localized cascade of deleterious effects initiated by the innate host immune system during revascularization procedures, and is designed to maximize the long term retention of left ventricular function

More recent studies show that our antibody also mitigates the preoteinuria associated with diabetic nephropathy DecImmune, located in Kendall Sq, was founded by Professors Michael Carroll of Childrens’ Hospital and Francis Moore of the Brigham and Womens’ Hospital DecImmune is supported by leading group of venture investors, experienced management and multiple Federal SBIR grants

Portfolio Name: EP Sciences

EP Sciences, LLC is a New York-based company founded in 2011 by the Coridea medical device incubator The company is developing a novel waveform to reduce the severe pain associated with implantable cardioverter defibrillator (ICD) shocks in patients at risk of sudden cardiac arrest While roughly 800,000 Americans have an implanted defibrillator, the fear of an initial shock, post-traumatic stress from having experienced a shock, and the risk of receiving inappropriate shocks greatly limit the patient and physician acceptance of ICD therapy EP Sciences aims to improve the tolerance of ICD shocks to better assist patients suffering from ventricular fibrillation and other life-threatening cardiac arrhythmias

FineHeart is a French medical device company focused on creating innovative technologies in the cardiovascular space

FineHeart has developed the ICOMS (Implantable Cardiac Output Management System), a novel, wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility It is a game changing therapy for long term circulatory assistance in severe heart failure patients FineHeart was founded by a team of four internationally renowned cardiologists, led by Dr Stéphane Garrigue (ICOMS Inventor) and Dr Philippe Ritter, co-inventor of cardiac resynchronization therapy, with a vision of making a miniaturized, fully implantable, pulsatile circulatory support system that would overcome many of the challenges associated with left ventricular assist devices (LVADs) currently on market The overarching goal is to restore normal cardiac output and allow heart failure patients to return to a normal quality of life The founding scientists and clinicians have been joined by four managers with specific expertise in the medical device industry, led by Arnaud Mascarell (CEO)

Portfolio Name: GI Windows

GI Windows is a clinical-stage medical device company developing a non-surgical approach to create anastomoses in the GI tract Their patented self-assembling magnets are designed to enable an incision-less and durable intestinal bypass to treat chronic diseases, such as Type-2 Diabetes and Obesity, without the cost and invasiveness of surgical interventions

Portfolio Name: Adient Medical

Adient’s mission is the development of absorbable medical devices with the premise that implants should be safe and efficacious during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications